Shanghai Meiyue Biotech Development Co. Ltd. has patented heterocyclic derivatives acting as KIT (c-KIT) inhibitors. They are reported to be useful for the treatment of autoimmune, metabolic disease, cancer, diabetes, fibrosis, urticaria, inflammatory and respiratory disorders, among others.